No EU Fast Track for AZ’s Imfinzi In Stage III Lung Cancer

 
• By Maureen Kenny

AstraZeneca will be disappointed at the European Medicines Agency’s refusal of its request for accelerated assessment of Imfinzi in earlier-stage lung cancer as the company is aiming to take hold of this new indication and run with it.

Darts
AstraZeneca missed its target of getting EU speedy review for Infimzi • Source: Shutterstock

More from Immuno-oncology

More from Anticancer